Status:
COMPLETED
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Lead Sponsor:
Alcon Research
Conditions:
Dry Eye Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
Detailed Description
Qualified subjects will enter a 14-day run-in period, followed by a 13-week randomized treatment period, for a total individual duration of participation of approximately 15 weeks. During the run-in p...
Eligibility Criteria
Inclusion
- Key
- Have a previous history of DED, clinician diagnosed or patient reported, within the previous 6 months prior to the Screening visit.
- Have used artificial tears for DED symptoms within 2 months prior to the Screening visit.
- Corrected visual acuity equal to or better than logarithm Minimum angle of reflection (logMar) +0.7 (Snellen equivalent equal to or better than 20/100), as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at both the Screening and Baseline visits.
- Good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history.
- Other protocol specified inclusion criteria may apply.
- Key
Exclusion
- History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety.
- Current evidence of other significant ophthalmic disease requiring topical medication (e.g., glaucoma, ocular hypertension), or other ophthalmic disease which the investigator believes may interfere with study findings or interpretation.
- History of ocular surgery within 1 year prior to the Screening visit; history of corneal transplant in one or both eyes.
- Use of contact lenses in either eye within 7 days prior to the Screening visit or planned use during the study.
- Regular use, as assessed by the investigator, of lid hygiene or heat masks within 14 days prior to the Screening visit or any planned use during the study.
- Use of lid heating therapy or Meibomian gland probing/therapeutic expression within 1 year prior to the Screening visit or anticipated during the study.
- Other protocol-specified exclusion criteria may apply.
Key Trial Info
Start Date :
October 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2025
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT06544694
Start Date
October 8 2024
End Date
March 21 2025
Last Update
August 12 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Butchertown Clinical Trials
Louisville, Kentucky, United States, 40206
2
Oculus Research
Garner, North Carolina, United States, 27529
3
Wilmington Eye
Leland, North Carolina, United States, 28451
4
CORE, Inc.
Shelby, North Carolina, United States, 28150